Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care
Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care
This study will compare the health and well being of children treated with a modified stem
 cell transplantation procedure for chronic granulomatous disease (CGD) with that of children
 receiving standard of care treatment. CGD is an inherited disorder of neutrophils-a type of
 infection-fighting white blood cell-that leaves patients vulnerable to life-threatening
 infections. Standard treatment with antibiotics, and sometimes surgery, is not always
 successful, and patients with persisting infections have a poor long-term prognosis.

 Transplantation of donated stem cells (cells produced by the bone marrow that mature into
 white and red blood cells and platelets) can improve immune function in patients with CGD and
 possibly cure the disease. However, this procedure carries a significant risk of death,
 because it requires complete suppression of the immune system with high-dose chemotherapy. In
 addition, lymphocytes-another type of infection-fighting white blood cell-from the donor may
 cause what is called graft versus host disease (GvHD), in which the donor cells 'see'
 patient's cells as foreign and mount an immune response to reject them. To try to reduce
 these risks, patients in this study will be given low-dose chemotherapy that is easier for
 the body to tolerate and involves a shorter period of complete immune suppression. Also, the
 donor's lymphocytes will be removed from the rest of the stem cells to be transplanted,
 reducing the risk of GvHD.

 Patients with CGD between 2 and 17 years of age who 1) are currently free of active
 infection, and 2) have a history of at least one life-threatening infection or a family
 member with CGD and a history of at least one life-threatening infection, and 3) a family
 member that is a suitable donor may be eligible for this study. Candidates will have a
 medical history, physical examination and blood tests, lung and heart function tests, x-rays
 or CT scans of the body, and dental and eye examinations. They will fill out questionnaires
 that measure emotional well being, quality of life, and intelligence (ability to learn and
 understand).

 Stem cells will be collected from both the patient and donor. To do this, the hormone G-CSF
 will be injected under the skin for several days to move stem cells from the bone marrow to
 the bloodstream. Then, the stem cells will be collected by apheresis. In this procedure the
 blood is drawn through a needle placed in one arm and pumped into a machine where the
 required cells are separated out and removed. Then, the rest of the blood is returned through
 a needle in the other arm.

 Several days before the transplant procedure, patients will start a 'conditioning regimen' of
 chemotherapy with cyclophosphamide, fludarabine and Campath 1H. When the conditioning therapy
 is completed, the donor's stem cells will be infused. To help prevent rejection of donor
 cells, cyclosporine will be given by mouth or by vein starting 1 month after the transplant
 procedure.

 The average hospital stay for stem cell transplantation is 21 days. After discharge, patients
 will return to the NIH clinic for follow-up clinic visits weekly or twice weekly for 2 to 3
 months. These visits will include a symptom check, physical examination and blood tests.
 Subsequent clinic visits will be scheduled 1 to 3 times a year for at least 5 years.
Chronic Granulomatous Disease (CGD) is one of several inherited disorders of leukocyte
 function. Patients are profoundly immunocompromised and plagued early in life with recurrent
 and often life threatening infections. Allogeneic stem cell transplantation significantly
 improves immune function in patients with CGD. The primary objective of this study is to
 investigate efficacy of a novel approach to allogeneic stem cell transplantation, which is
 designed to promote partial or complete donor stem cell engraftment (hematopoietic chimerism)
 with reduced transplant related morbidity and mortality. In an attempt to reduce toxicity
 from pre-transplant bone marrow conditioning, a highly immunosuppressive, low intensity bone
 marrow conditioning regimen will be used. Patients will be transplanted with peripheral blood
 stem cells from an HLA identical family member. The graft will be enriched for hematopoietic
 stem cells in an attempt to decrease the risk of graft versus host disease. Donor T-cells
 will be infused at various time points following the transplant to augment donor
 hematopoietic chimerism and aid in immune reconstitution. Patients treated with this approach
 will be compared to patients who are considered transplant-eligible but lack an HLA identical
 family member. These patients will be treated using the current standard of care. The primary
 end points of this study are to demonstrate reduced incidence of CGD-like infections in the
 transplanted patients compared to the controls (efficacy) with acceptable incidence of acute
 and chronic graft versus host disease and transplant related mortality (safety). Long term
 follow up data from transplanted patients and concurrent controls will be analyzed to confirm
 the association between establishment of hematopoietic chimerism and clinical benefit.
INCLUSION CRITERIA

 The following conditions must be met before a patient may be enrolled in the study:

 Patients ages 2 to 17 years; minimum weight of 12 kg.

 DHR proven chronic granulomatous disease with gp91 phox or p22 phox deficiency.

 History of at least one life-threatening infection (defined as any infection requiring
 treatment with intravenous antibiotic therapy) or a family member with CGD and a history of
 life-threatening infection.

 Free of active infection.

 Patients with consenting HLA-matched related donors that meet donor selection criteria
 (test patients), or patients without an eligible HLA-matched related donor (control
 patients). Patients with eligible donors who choose not to undergo stem cell
 transplantation or patients with eligible but non-consenting donors may be enrolled in the
 control arm of the study. Patients enrolled in the control arm who complete a 24 month
 follow-up period may enroll in the transplant arm should an eligible, consenting donor
 become available.

 Patients with adequate organ function as measured by:

 Cardiac: Asymptomatic or, if symptomatic, then left ventricular ejection fraction at rest
 must be greater than 35%.

 Hepatic: SGOT within 4 times normal range and total bilirubin less than 2mg/dL.

 Renal: Creatinine clearance greater than or equal to 50 mL/min/ 1.73m(2). A maximum age
 adjusted serum creatinine will be used for patients who are unable to provide an accurate
 24 hour urine collection. For children less than or equal to 5 years of age, the maximum
 serum creatinine (mg/dl) is 0.8; for children whose age is greater than 5 to less than or
 equal to 10, the maximum serum creatinine (mg/dl) is 1.0; for children whose age is greater
 than 10 to less than or equal to age 15, the maximum serum creatinine (mg/dl) is 1.2; and
 for children whose age is greater than 15, the maximum serum creatinine (mg/dl) is 1.5.

 Pulmonary: DLCO (diffusion capacity) and FEV1 greater than 45 percent of predicted
 (corrected for hemoglobin). Minors in whom pulmonary function tests are not possible will
 be evaluated for significant pulmonary dysfunction by a pulmonary consultant.

 Written informed consent/assent conforming to institutional guidelines obtained from
 patient and parent.

 Absence of co-existing medical problems that would significantly increase the risk of a
 transplant procedure in the judgment of the principal investigator.

 EXCLUSION CRITERIA:

 Any one of the following conditions eliminates a patient from participating in this
 protocol:

 Female patients who are pregnant or lactating.

 ECOG performance status of 2 or more or less than 50 percent on the Lansky scale for ages
 0-10.

 Seropositivity for HIV due to excessive risk of infection and neurotoxicity of
 antiretroviral medications.

 Evidence of rapid deterioration due to progressive infection and/or organ damage.

 Malignant diseases liable to relapse or progress within 5 years.

 DONOR SELECTION:

 Donors must be fit to receive G-CSF and give peripheral blood stem cells (normal blood
 count, normotensive, no history of stroke, no history of severe heart disease, greater than
 12kg).

 Related to the patient and HLA-phenotypically identical with the patient for HLA-A, B and
 DRB1 alleles. Matching assessed minimally by serology for Class I and DNA typing for Class
 II antigens.

 Female x-linked CGD carriers must have greater than 30 percent normal neutrophils.

 If donor is a sibling who is a minor, he/ she is the oldest eligible sibling and no adult
 siblings are eligible donors.

 Written informed consent from donor. Donors who are minors will be evaluated by a social
 worker, psychologist or psychiatrist prior to the assent process to determine willingness
 to participate. If willingness to participate has been confirmed, informed consent will be
 obtained from adult parent or legal guardian. Informed assent will be obtained from minor
 donor in the presence of a third party who will assess comprehension and voluntary
 participation.